{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T07:44:42Z","timestamp":1791531882763,"version":"4.3.4"},"reference-count":198,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Disease Clinics of North America"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.idc.2020.05.001","type":"journal-article","created":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T05:33:05Z","timestamp":1601443985000},"page":"773-819","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":126,"title":["Resistance to Novel \u03b2-Lactam\u2013\u03b2-Lactamase Inhibitor Combinations"],"prefix":"10.1016","volume":"34","author":[{"given":"Krisztina M.","family":"Papp-Wallace","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Mack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena A.","family":"Taracila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Bonomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.idc.2020.05.001_bib1","doi-asserted-by":"crossref","first-page":"a025247","DOI":"10.1101\/cshperspect.a025247","article-title":"\u03b2-lactams and \u03b2-lactamase inhibitors: an overview","volume":"6","author":"Bush","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.idc.2020.05.001_bib2","series-title":"Outpatient Antibiotic prescriptions \u2014 United States, 2016","year":"2018"},{"issue":"1","key":"10.1016\/j.idc.2020.05.001_bib3","doi-asserted-by":"crossref","first-page":"120143","DOI":"10.1098\/rsob.120143","article-title":"L-form bacteria, cell walls and the origins of life","volume":"3","author":"Errington","year":"2013","journal-title":"Open Biol"},{"issue":"1","key":"10.1016\/j.idc.2020.05.001_bib4","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1146\/annurev.bi.38.070169.002441","article-title":"Structure and Biosynthesis of the Bacterial Cell Wall","volume":"38","author":"Osborn","year":"1969","journal-title":"Annu Rev Biochem"},{"issue":"4","key":"10.1016\/j.idc.2020.05.001_bib5","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1073\/pnas.54.4.1133","article-title":"Mechanism of action of penicillins: a proposal based on their structural similarity to acyl-D-alanyl-D-alanine","volume":"54","author":"Tipper","year":"1965","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"6","key":"10.1016\/j.idc.2020.05.001_bib6","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.cell.2014.11.017","article-title":"Beta-lactam antibiotics induce a lethal malfunctioning of the bacterial cell wall synthesis machinery","volume":"159","author":"Cho","year":"2014","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.idc.2020.05.001_bib7","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s10156-013-0640-7","article-title":"The ABCD\u2019s of \u03b2-lactamase nomenclature","volume":"19","author":"Bush","year":"2013","journal-title":"J\u00a0Infect Chemother"},{"issue":"Pt 1","key":"10.1016\/j.idc.2020.05.001_bib8","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1042\/bj2760269","article-title":"A\u00a0standard numbering scheme for the class A \u03b2-lactamases","volume":"276","author":"Ambler","year":"1991","journal-title":"Biochem J"},{"key":"10.1016\/j.idc.2020.05.001_bib9","article-title":"A\u00a0standard numbering scheme for class C \u03b2-lactamases","author":"Mack","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"6255","key":"10.1016\/j.idc.2020.05.001_bib10","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/343284a0","article-title":"Refined crystal structure of \u03b2-lactamase from Citrobacter freundii indicates a mechanism for \u03b2-lactam hydrolysis","volume":"343","author":"Oefner","year":"1990","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.idc.2020.05.001_bib11","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/0006-2952(94)00502-D","article-title":"The enigmatic catalytic mechanism of active-site serine \u03b2-lactamases","volume":"49","author":"Galleni","year":"1995","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"10.1016\/j.idc.2020.05.001_bib12","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0969-2126(02)00725-6","article-title":"Structural milestones in the reaction pathway of an amide hydrolase: substrate, acyl, and product complexes of cephalothin with ampc \u03b2-lactamase","volume":"10","author":"Beadle","year":"2002","journal-title":"Structure"},{"key":"10.1016\/j.idc.2020.05.001_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/pro.60","article-title":"Re-examining the role of Lys67 in class C \u03b2-lactamase catalysis","author":"Chen","year":"2009","journal-title":"Protein Sci"},{"issue":"5","key":"10.1016\/j.idc.2020.05.001_bib14","doi-asserted-by":"crossref","first-page":"e0125832","DOI":"10.1371\/journal.pone.0125832","article-title":"Flexibility correlation between active site regions is conserved across four AmpC \u03b2-lactamase enzymes","volume":"10","author":"Brown","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.idc.2020.05.001_bib15","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1128\/CMR.00036-08","article-title":"AmpC \u03b2-lactamases","volume":"22","author":"Jacoby","year":"2009","journal-title":"Clin Microbiol Rev"},{"issue":"2","key":"10.1016\/j.idc.2020.05.001_bib16","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1365-2958.1994.tb01011.x","article-title":"Evolution of antibiotic resistance: several different amino acid substitutions in an active site loop alter the substrate profile of \u03b2-lactamase","volume":"12","author":"Palzkill","year":"1994","journal-title":"Mol Microbiol"},{"issue":"10","key":"10.1016\/j.idc.2020.05.001_bib17","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1021\/bi972127f","article-title":"Role of the \u03a9-loop in the activity, substrate specificity, and structure of class A \u03b2-lactamase","volume":"37","author":"Banerjee","year":"1998","journal-title":"Biochemistry"},{"issue":"29","key":"10.1016\/j.idc.2020.05.001_bib18","doi-asserted-by":"crossref","first-page":"10461","DOI":"10.1021\/bi980184i","article-title":"Effect of an amino acid insertion into the omega loop region of a class C \u03b2-lactamase on its substrate specificity","volume":"37","author":"Nukaga","year":"1998","journal-title":"Biochemistry"},{"issue":"32","key":"10.1016\/j.idc.2020.05.001_bib19","doi-asserted-by":"crossref","first-page":"10256","DOI":"10.1021\/bi9908787","article-title":"Structure of the extended-spectrum class C \u03b2-Lactamase of Enterobacter cloacae GC1, a natural mutant with a tandem tripeptide insertion","volume":"38","author":"Crichlow","year":"1999","journal-title":"Biochemistry"},{"issue":"1","key":"10.1016\/j.idc.2020.05.001_bib20","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1128\/CMR.00037-09","article-title":"Three decades of \u03b2-lactamase inhibitors","volume":"23","author":"Drawz","year":"2010","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"10.1016\/j.idc.2020.05.001_bib21","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1128\/CMR.1.1.109","article-title":"\u03b2-lactamase inhibitors from laboratory to clinic","volume":"1","author":"Bush","year":"1988","journal-title":"Clin Microbiol Rev"},{"issue":"29","key":"10.1016\/j.idc.2020.05.001_bib22","doi-asserted-by":"crossref","first-page":"11663","DOI":"10.1073\/pnas.1205073109","article-title":"Avibactam is a covalent, reversible, non\u2013\u03b2-lactam \u03b2-lactamase inhibitor","volume":"109","author":"Ehmann","year":"2012","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"2","key":"10.1016\/j.idc.2020.05.001_bib23","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.idc.2016.02.007","article-title":"New \u03b2-lactamase inhibitors in the clinic","volume":"30","author":"Papp-Wallace","year":"2016","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.idc.2020.05.001_bib24","unstructured":"Merck & Co., Inc. ZERBAXA (Ceftolozane and Tazobactam) for injection, for intravenous use. Whitehouse Station (NJ); 2019."},{"issue":"10","key":"10.1016\/j.idc.2020.05.001_bib25","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/civ097","article-title":"Ceftolozane\/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI)","volume":"60","author":"Solomkin","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2020.05.001_bib26","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jiac.2018.10.012","article-title":"The efficacy and safety of tazobactam\/ceftolozane in combination with metronidazole in Japanese patients with complicated intra-abdominal infections","volume":"25","author":"Mikamo","year":"2019","journal-title":"J\u00a0Infect Chemother"},{"issue":"7","key":"10.1016\/j.idc.2020.05.001_bib27","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1093\/jac\/dkw053","article-title":"Efficacy of ceftolozane\/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial","volume":"71","author":"Huntington","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.idc.2020.05.001_bib28","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jiac.2018.10.009","article-title":"The efficacy and safety of tazobactam\/ceftolozane in Japanese patients with uncomplicated pyelonephritis and complicated urinary tract infection","volume":"25","author":"Arakawa","year":"2019","journal-title":"J\u00a0Infect Chemother"},{"issue":"12","key":"10.1016\/j.idc.2020.05.001_bib29","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"10.1016\/j.idc.2020.05.001_bib30","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01589-17","article-title":"Genomics and susceptibility profiles of extensively drug-resistant Pseudomonas aeruginosa Isolates from Spain","volume":"61","author":"Del Barrio-Tofi\u00f1o","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.idc.2020.05.001_bib31","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1093\/jac\/dkz149","article-title":"ESBLs and resistance to ceftazidime\/avibactam and ceftolozane\/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa","volume":"74","author":"Ortiz de la Rosa","year":"2019","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.idc.2020.05.001_bib32","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.diagmicrobio.2018.10.004","article-title":"Diversity of resistance mechanisms in carbapenem-resistant Enterobacteriaceae at a health care system in Northern California, from 2013 to 2016","volume":"93","author":"Senchyna","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"8","key":"10.1016\/j.idc.2020.05.001_bib33","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00533-18","article-title":"In\u00a0vitro activity of imipenem-relebactam and ceftolozane-tazobactam against resistant gram-negative bacilli","volume":"62","author":"Schmidt-Malan","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.idc.2020.05.001_bib34","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02112-19","article-title":"Emergence of resistance to novel \u03b2-lactam-\u03b2-lactamase inhibitor combinations due to horizontally acquired AmpC (FOX-4) in Pseudomonas aeruginosa Sequence Type 308","volume":"64","author":"Fraile-Ribot","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.idc.2020.05.001_bib35","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00160-19","article-title":"Comparative activities of ceftazidime-avibactam and ceftolozane-tazobactam against enterobacteriaceae isolates producing extended-spectrum \u03b2-lactamases from U.S. Hospitals","volume":"63","author":"Castanheira","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.idc.2020.05.001_bib36","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/jac\/dkx136","article-title":"Activity of ceftolozane\/tazobactam against surveillance and \u201cproblem\u201d Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles","volume":"72","author":"Livermore","year":"2017","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"12","key":"10.1016\/j.idc.2020.05.001_bib37","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1128\/AAC.01802-13","article-title":"Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012)","volume":"57","author":"Farrell","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.idc.2020.05.001_bib38","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ijantimicag.2015.07.004","article-title":"In\u00a0vitro activity of ceftolozane\/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study","volume":"46","author":"Tato","year":"2015","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"10.1016\/j.idc.2020.05.001_bib39","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02125-17","article-title":"Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015","volume":"62","author":"Castanheira","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.idc.2020.05.001_bib40","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00675-18","article-title":"In\u00a0Vitro activity of ceftolozane-tazobactam against enterobacter cloacae complex clinical isolates with different \u03b2-lactam resistance phenotypes","volume":"62","author":"Robin","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2020.05.001_bib41","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.3389\/fmicb.2018.01422","article-title":"Interplay between membrane permeability and enzymatic barrier leads to antibiotic-dependent resistance in Klebsiella Pneumoniae","volume":"9","author":"Nicolas-Chanoine","year":"2018","journal-title":"Front Microbiol"},{"issue":"9","key":"10.1016\/j.idc.2020.05.001_bib42","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1128\/AAC.00680-12","article-title":"Pan-\u03b2-lactam resistance development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, penicillin-binding protein profiles, and binding affinities","volume":"56","author":"Moy\u00e1","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.idc.2020.05.001_bib43","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1128\/AAC.00860-06","article-title":"In vitro and in\u00a0vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa","volume":"51","author":"Takeda","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.idc.2020.05.001_bib44","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1128\/AAC.01410-08","article-title":"Extended-spectrum cephalosporinases in Pseudomonas aeruginosa","volume":"53","author":"Rodr\u00edguez-Mart\u00ednez","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.idc.2020.05.001_bib45","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1093\/jac\/dkq248","article-title":"Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus \u03b2-lactamase-producing Enterobacteriaceae","volume":"65","author":"Livermore","year":"2010","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.idc.2020.05.001_bib46","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/14787210.2018.1447381","article-title":"Ceftolozane\/tazobactam: place in therapy","volume":"16","author":"Giacobbe","year":"2018","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"4","key":"10.1016\/j.idc.2020.05.001_bib47","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1128\/AAC.26.4.580","article-title":"Comparative activities of the \u03b2-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin","volume":"26","author":"Aronoff","year":"1984","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.idc.2020.05.001_bib48","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1128\/AAC.01009-09","article-title":"Updated functional classification of \u03b2-lactamases","volume":"54","author":"Bush","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.idc.2020.05.001_bib49","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1128\/AAC.37.4.851","article-title":"Kinetic interactions of tazobactam with \u03b2-lactamases from all major structural classes","volume":"37","author":"Bush","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2020.05.001_bib50","article-title":"In\u00a0Vivo resistance to ceftolozane\/tazobactam in Pseudomonas aeruginosa Arising by AmpC- and Non-AmpC-mediated pathways","author":"Skoglund","year":"2018","journal-title":"Case Rep Infect Dis"},{"issue":"10","key":"10.1016\/j.idc.2020.05.001_bib51","doi-asserted-by":"crossref","first-page":"6248","DOI":"10.1128\/AAC.00825-15","article-title":"Mutations in \u03b2-lactamase AmpC increase resistance of Pseudomonas aeruginosa isolates to antipseudomonal cephalosporins","volume":"59","author":"Berrazeg","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.idc.2020.05.001_bib52","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/jac\/dkx424","article-title":"Mechanisms leading to in\u00a0vivo ceftolozane\/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa","volume":"73","author":"Fraile-Ribot","year":"2018","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.idc.2020.05.001_bib53","article-title":"Activity of imipenem\/relebactam against a large collection of Pseudomonas aeruginosa clinical isolates and isogenic \u03b2-lactam resistant mutants","author":"Fraile-Ribot","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.idc.2020.05.001_bib54","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.ijantimicag.2019.02.022","article-title":"Phylogenetic analysis of resistance to ceftazidime\/avibactam, ceftolozane\/tazobactam and carbapenems in piperacillin\/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients","volume":"53","author":"Zamudio","year":"2019","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"10.1016\/j.idc.2020.05.001_bib55","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1128\/AAC.02462-13","article-title":"Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple Mutations leading to overexpression and structural modification of AmpC","volume":"58","author":"Cabot","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.idc.2020.05.001_bib56","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1007\/s10096-018-3361-0","article-title":"Ceftolozane\/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: experience from the Balearic Islands","volume":"37","author":"D\u00edaz-Ca\u00f1estro","year":"2018","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"12","key":"10.1016\/j.idc.2020.05.001_bib57","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01183-17","article-title":"Emergence of ceftolozane-tazobactam-resistant Pseudomonas aeruginosa during treatment is mediated by a single AmpC structural mutation","volume":"61","author":"MacVane","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.idc.2020.05.001_bib58","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/cid\/cix182","article-title":"Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: clinical effectiveness and evolution of resistance","volume":"65","author":"Haidar","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.idc.2020.05.001_bib59","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1093\/jac\/dkz147","article-title":"Spanish nationwide survey on Pseudomonas aeruginosa antimicrobial resistance mechanisms and epidemiology","volume":"74","author":"Del Barrio-Tofi\u00f1o","year":"2019","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.idc.2020.05.001_bib60","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01637-19","article-title":"A\u00a02.5-years within-patient evolution of a Pseudomonas aeruginosa with in\u00a0vivo acquisition of ceftolozane-tazobactam and ceftazidime-avibactam resistance upon treatment","author":"Boulant","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2020.05.001_bib61","article-title":"Mechanisms of high-level ceftolozane\/tazobactam resistance in Pseudomonas aeruginosa from a severely neutropenic patient and treatment success from synergy with tobramycin","author":"So","year":"2019","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.idc.2020.05.001_bib62","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02085-18","article-title":"Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa","volume":"9","author":"Barnes","year":"2018","journal-title":"mBio"},{"issue":"1","key":"10.1016\/j.idc.2020.05.001_bib63","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01970-17","article-title":"Activity of ceftolozane-tazobactam against carbapenem-resistant, non-carbapenemase-producing Pseudomonas aeruginosa and associated resistance mechanisms","volume":"62","author":"Wi","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.idc.2020.05.001_bib64","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1128\/CMR.00040-09","article-title":"Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms","volume":"22","author":"Lister","year":"2009","journal-title":"Clin Microbiol Rev"},{"issue":"6","key":"10.1016\/j.idc.2020.05.001_bib65","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1093\/femsre\/fux043","article-title":"Diversity and regulation of intrinsic \u03b2-lactamases from non-fermenting and other Gram-negative opportunistic pathogens","volume":"41","author":"Juan","year":"2017","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.idc.2020.05.001_bib66","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1749-6632.2012.06813.x","article-title":"Bacterial cell-wall recycling","volume":"1277","author":"Johnson","year":"2013","journal-title":"Ann N Y Acad Sci"},{"issue":"12","key":"10.1016\/j.idc.2020.05.001_bib67","doi-asserted-by":"crossref","first-page":"5952","DOI":"10.1021\/acs.chemrev.8b00277","article-title":"Cell-wall recycling of the gram-negative bacteria and the nexus to antibiotic resistance","volume":"118","author":"Dik","year":"2018","journal-title":"Chem Rev"},{"issue":"11","key":"10.1016\/j.idc.2020.05.001_bib68","doi-asserted-by":"crossref","first-page":"6844","DOI":"10.1128\/AAC.03681-14","article-title":"Mutation-driven \u03b2-lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible Pseudomonas aeruginosa isolates from U.S. hospitals","volume":"58","author":"Castanheira","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.idc.2020.05.001_bib69","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1128\/AAC.01104-09","article-title":"Activity of a new cephalosporin, CXA-101 (FR264205), against \u03b2-lactam-resistant Pseudomonas aeruginosa mutants selected in\u00a0vitro and after antipseudomonal treatment of intensive care unit patients","volume":"54","author":"Moya","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.idc.2020.05.001_bib70","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1021\/acsinfecdis.8b00240","article-title":"Genetic, biochemical, and structural characterization of CMY-136 \u03b2-lactamase, a peculiar CMY-2 variant","volume":"5","author":"Zavala","year":"2019","journal-title":"ACS Infect Dis"},{"issue":"8","key":"10.1016\/j.idc.2020.05.001_bib71","doi-asserted-by":"crossref","first-page":"4348","DOI":"10.1128\/jb.172.8.4348-4351.1990","article-title":"Extension of the substrate spectrum by an amino acid substitution at residue 219 in the Citrobacter freundii cephalosporinase","volume":"172","author":"Tsukamoto","year":"1990","journal-title":"J\u00a0Bacteriol"},{"issue":"5","key":"10.1016\/j.idc.2020.05.001_bib72","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1093\/jac\/dks520","article-title":"Detection of clonally related Escherichia coli isolates producing different CMY \u03b2-lactamases from a cystic fibrosis patient","volume":"68","author":"Cr\u00e9met","year":"2013","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.idc.2020.05.001_bib73","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1128\/AAC.42.1.176","article-title":"Sequences of homologous \u03b2-lactamases from clinical isolates of Serratia marcescens with different substrate specificities","volume":"42","author":"Matsumura","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2020.05.001_bib74","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01375-19","article-title":"Acquisition of class C \u03b2-lactamase PAC-1 by ST664 strains of Pseudomonas aeruginosa","author":"Bour","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.idc.2020.05.001_bib75","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01809-18","article-title":"Acquisition of Extended-Spectrum \u03b2-Lactamase GES-6 Leading to Resistance to Ceftolozane-Tazobactam Combination in Pseudomonas aeruginosa","volume":"63","author":"Poirel","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.idc.2020.05.001_bib76","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1093\/jac\/dkz379","article-title":"Evaluation of in\u00a0vitro activity of ceftazidime\/avibactam and ceftolozane\/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar","volume":"74","author":"Sid Ahmed","year":"2019","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"7","key":"10.1016\/j.idc.2020.05.001_bib77","doi-asserted-by":"crossref","first-page":"ofz273","DOI":"10.1093\/ofid\/ofz273","article-title":"Extensively Drug-Resistant Pseudomonas aeruginosa ST309 harboring tandem guiana extended spectrum \u03b2-lactamase enzymes: a newly emerging threat in the United States","volume":"6","author":"Khan","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"9","key":"10.1016\/j.idc.2020.05.001_bib78","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01117-17","article-title":"In\u00a0vivo emergence of resistance to novel cephalosporin-\u03b2-lactamase inhibitor combinations through the duplication of amino acid D149 from OXA-2 \u03b2-Lactamase (OXA-539) in Sequence Type 235 Pseudomonas aeruginosa","volume":"61","author":"Fraile-Ribot","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.idc.2020.05.001_bib79","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01110-19","article-title":"Challenging antimicrobial susceptibility and evolution of resistance (OXA-681) during treatment of a long-term nosocomial infection caused by a Pseudomonas aeruginosa ST175 Clone","volume":"63","author":"Arca-Su\u00e1rez","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.idc.2020.05.001_bib80","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1128\/AAC.00834-09","article-title":"Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains","volume":"54","author":"Juan","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2020.05.001_bib81","unstructured":"Clinical and Laboratory Standards Institute (CLSI). M100: Performance Standards for Antimicrobial Susceptibility Testing. 30th edition. 2020."},{"key":"10.1016\/j.idc.2020.05.001_bib82","unstructured":"Allergan USA, Inc. AVYCAZ (Ceftazidime and Avibactam) for Injection, for Intravenous Use. Madison (NJ): 2019."},{"issue":"2","key":"10.1016\/j.idc.2020.05.001_bib83","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1128\/AAC.01896-13","article-title":"Contemporary diversity of \u03b2-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent \u03b2-lactamase groups","volume":"58","author":"Castanheira","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.idc.2020.05.001_bib84","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1128\/AAC.03042-15","article-title":"In\u00a0vitro susceptibility to ceftazidime-avibactam of carbapenem-nonsusceptible enterobacteriaceae isolates collected during the INFORM Global Surveillance Study (2012 to 2014)","volume":"60","author":"de Jonge","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"39","key":"10.1016\/j.idc.2020.05.001_bib85","doi-asserted-by":"crossref","first-page":"27960","DOI":"10.1074\/jbc.M113.485979","article-title":"Kinetics of avibactam inhibition against Class A, C, and D \u03b2-lactamases","volume":"288","author":"Ehmann","year":"2013","journal-title":"J\u00a0Biol Chem"},{"issue":"5","key":"10.1016\/j.idc.2020.05.001_bib86","first-page":"1396","article-title":"In\u00a0vitro activity of ceftazidime\/avibactam against urinary isolates from patients in a Phase 3 clinical trial programme for the treatment of complicated urinary tract infections","volume":"72","author":"Stone","year":"2017","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"11","key":"10.1016\/j.idc.2020.05.001_bib87","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program","volume":"62","author":"Mazuski","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2020.05.001_bib88","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"10.1016\/j.idc.2020.05.001_bib89","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/INF.0000000000002392","article-title":"Safety and efficacy of ceftazidime-avibactam plus metronidazole in the treatment of children \u22653\u00a0months to <18 years with complicated intra-abdominal infection: results from a phase 2, randomized, controlled trial","volume":"38","author":"Bradley","year":"2019","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"10.1016\/j.idc.2020.05.001_bib90","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program","volume":"63","author":"Wagenlehner","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2020.05.001_bib91","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"10.1016\/j.idc.2020.05.001_bib92","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/INF.0000000000002395","article-title":"Safety and efficacy of ceftazidime-avibactam in the treatment of children \u22653\u00a0months to <18 years with complicated urinary tract infection: results from a phase 2 randomized, controlled trial","volume":"38","author":"Bradley","year":"2019","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"10.1016\/j.idc.2020.05.001_bib93","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1128\/AAC.17.5.876","article-title":"GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity","volume":"17","author":"O\u2019Callaghan","year":"1980","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.idc.2020.05.001_bib94","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1128\/AAC.17.5.807","article-title":"GR-20263: a new aminothiazolyl cephalosporin with high activity against Pseudomonas and Enterobacteriaceae","volume":"17","author":"Verbist","year":"1980","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.idc.2020.05.001_bib95","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1093\/jac\/dkq306","article-title":"In\u00a0vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters","volume":"65","author":"Mushtaq","year":"2010","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.idc.2020.05.001_bib96","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1586\/14787210.6.6.805","article-title":"Cefepime: a reappraisal in an era of increasing antimicrobial resistance","volume":"6","author":"Endimiani","year":"2008","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"6","key":"10.1016\/j.idc.2020.05.001_bib97","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1128\/AAC.02247-12","article-title":"Structural Insight into Potent Broad-Spectrum Inhibition with Reversible Recyclization Mechanism: Avibactam in Complex with CTX-M-15 and Pseudomonas aeruginosa AmpC \u03b2-Lactamases","volume":"57","author":"Lahiri","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.idc.2020.05.001_bib98","doi-asserted-by":"crossref","first-page":"5704","DOI":"10.1128\/AAC.03057-14","article-title":"Avibactam and class C \u03b2-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance","volume":"58","author":"Lahiri","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.idc.2020.05.001_bib99","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01224-17","article-title":"New Delhi metallo-\u03b2-lactamase 1 catalyzes avibactam and aztreonam hydrolysis","volume":"61","author":"Lohans","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.idc.2020.05.001_bib100","doi-asserted-by":"crossref","first-page":"6605","DOI":"10.1128\/AAC.01165-15","article-title":"First report of ceftazidime-avibactam resistance in a KPC-3-expressing Klebsiella pneumoniae Isolate","volume":"59","author":"Humphries","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.idc.2020.05.001_bib101","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1093\/cid\/ciw639","article-title":"Editorial commentary: ceftazidime-avibactam and carbapenem-resistant enterobacteriaceae: \u201cwe\u2019re gonna need a bigger boat.\u201d","volume":"63","author":"Spellberg","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.idc.2020.05.001_bib102","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1093\/jac\/dkv094","article-title":"Activity of ceftazidime\/avibactam against isogenic strains of Escherichia coli containing KPC and SHV \u03b2-lactamases with single amino acid substitutions in the \u03a9-loop","volume":"70","author":"Winkler","year":"2015","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"9","key":"10.1016\/j.idc.2020.05.001_bib103","doi-asserted-by":"crossref","first-page":"5324","DOI":"10.1128\/AAC.00678-15","article-title":"In\u00a0vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase","volume":"59","author":"Livermore","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.idc.2020.05.001_bib104","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02097-16","article-title":"Emergence of ceftazidime-avibactam resistance due to plasmid-borne blakpc-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.idc.2020.05.001_bib105","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/ciw636","article-title":"Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant enterobacteriaceae infections","volume":"63","author":"Shields","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.idc.2020.05.001_bib106","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00451-17","article-title":"Impaired inhibition by avibactam and resistance to the ceftazidime-avibactam combination due to the D179Y substitution in the KPC-2 \u03b2-lactamase","volume":"61","author":"Compain","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.idc.2020.05.001_bib107","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00079-17","article-title":"In\u00a0vitro selection of meropenem resistance among ceftazidime-avibactam-resistant, meropenem-susceptible Klebsiella pneumoniae isolates with variant KPC-3 carbapenemases","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.idc.2020.05.001_bib108","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02101-17","article-title":"Successive emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in blaKPC-2-Harboring Klebsiella pneumoniae sequence type 307 isolates","volume":"62","author":"Giddins","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.idc.2020.05.001_bib109","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1093\/jac\/dkz330","article-title":"Emergence of ceftazidime\/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in\u00a0vivo","volume":"74","author":"G\u00f6ttig","year":"2019","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.idc.2020.05.001_bib110","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00408-18","article-title":"Analyses of a ceftazidime-avibactam-resistant Citrobacter freundii Isolate Carrying blaKPC-2 Reveals a Heterogenous Population and Reversible Genotype","volume":"3","author":"Castanheira","year":"2018","journal-title":"mSphere"},{"issue":"8","key":"10.1016\/j.idc.2020.05.001_bib111","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01018-18","article-title":"Colistin does not potentiate ceftazidime-avibactam killing of carbapenem-resistant enterobacteriaceae in\u00a0vitro or suppress emergence of ceftazidime-avibactam resistance","volume":"62","author":"Shields","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.idc.2020.05.001_bib112","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/jac\/dky082","article-title":"In\u00a0vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime\/avibactam treatment","volume":"73","author":"Gaibani","year":"2018","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.idc.2020.05.001_bib113","doi-asserted-by":"crossref","first-page":"ofx101","DOI":"10.1093\/ofid\/ofx101","article-title":"Emergence of ceftazidime-avibactam resistance and restoration of carbapenem susceptibility in klebsiella pneumoniae carbapenemase-producing K pneumoniae: a case report and review of literature","volume":"4","author":"Shields","year":"2017","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2020.05.001_bib114","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02497-17","article-title":"Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant enterobacteriaceae infections","volume":"62","author":"Shields","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.idc.2020.05.001_bib115","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/phar.2184","article-title":"Suboptimal clinical response rates with newer antibiotics among patients with moderate renal impairment: review of the literature and potential pharmacokinetic and pharmacodynamic considerations for observed findings","volume":"38","author":"Bidell","year":"2018","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.idc.2020.05.001_bib116","article-title":"Monitoring Ceftazidime-Avibactam (CAZ-AVI) and Aztreonam (ATM) Concentrations in the Treatment of a Bloodstream Infection Caused by a Multidrug-Resistant Enterobacter sp. Carrying both KPC-4 and NDM-1 carbapenemases","author":"Yasmin","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2020.05.001_bib117","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02048-18","article-title":"Effects of KPC Variant and Porin Genotype on the In\u00a0Vitro activity of meropenem-vaborbactam against carbapenem-resistant enterobacteriaceae","volume":"63","author":"Wilson","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.idc.2020.05.001_bib118","doi-asserted-by":"crossref","first-page":"763.e5-e8","DOI":"10.1016\/j.cmi.2019.03.011","article-title":"Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime-avibactam","volume":"25","author":"Galani","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.idc.2020.05.001_bib119","article-title":"Emergence of ceftazidime\/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China","author":"Zhang","year":"2019","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10.1016\/j.idc.2020.05.001_bib120","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01551-18","article-title":"Meropenem-vaborbactam as salvage therapy for ceftazidime-avibactam-resistant Klebsiella pneumoniae bacteremia and abscess in a liver transplant recipient","volume":"63","author":"Athans","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2020.05.001_bib121","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.2147\/IDR.S207993","article-title":"Molecular and phenotypical characterization of two cases of antibiotic-driven ceftazidime-avibactam resistance in blaKPC-3-harboring Klebsiella pneumoniae","volume":"12","author":"Venditti","year":"2019","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.idc.2020.05.001_bib122","article-title":"Use of carbapenems in the combined treatment of emerging ceftazidime\/avibactam-resistant and carbapenem-susceptible KPC-producing Klebsiella pneumoniae infections: report of a case and review of the literature","author":"Cano","year":"2019","journal-title":"J\u00a0Glob Antimicrob Resist"},{"key":"10.1016\/j.idc.2020.05.001_bib123","article-title":"Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime\/avibactam: Epidemiology and genomic characterization","author":"Gaibani","year":"2019","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"10.1016\/j.idc.2020.05.001_bib124","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.diagmicrobio.2019.05.009","article-title":"Evaluation of a rapid immunochromatographic test for detection of KPC in clinical isolates of Enterobacteriaceae and Pseudomonas species","volume":"95","author":"Wozniak","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2020.05.001_bib125","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1093\/jac\/dkz026","article-title":"Ceftazidime\/avibactam resistance associated with L169P mutation in the omega loop of KPC-2","volume":"74","author":"Hemarajata","year":"2019","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"8","key":"10.1016\/j.idc.2020.05.001_bib126","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1093\/jac\/dkz209","article-title":"Unravelling ceftazidime\/avibactam resistance of KPC-28, a KPC-2 variant lacking carbapenemase activity","volume":"74","author":"Oueslati","year":"2019","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"19","key":"10.1016\/j.idc.2020.05.001_bib127","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2019.24.19.1900256","article-title":"Emergence of ceftazidime-avibactam-resistant Klebsiella pneumoniae during treatment, Finland, 2018","volume":"24","author":"R\u00e4is\u00e4nen","year":"2019","journal-title":"Euro Surveill"},{"key":"10.1016\/j.idc.2020.05.001_bib128","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01111-19","article-title":"Phenotypic, biochemical and genetic analysis of KPC-41, a KPC-3 variant conferring resistance to ceftazidime-avibactam and exhibiting reduced carbapenemase activity","author":"Mueller","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.idc.2020.05.001_bib129","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00528-17","article-title":"Klebsiella pneumoniae carbapenemase-2 (KPC-2), substitutions at ambler position asp179, and resistance to ceftazidime-avibactam: unique antibiotic-resistant phenotypes emerge from \u03b2-lactamase protein engineering","volume":"8","author":"Barnes","year":"2017","journal-title":"mBio"},{"issue":"7","key":"10.1016\/j.idc.2020.05.001_bib130","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1128\/AAC.04406-14","article-title":"Variants of \u03b2-lactamase KPC-2 that are resistant to inhibition by avibactam","volume":"59","author":"Papp-Wallace","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.idc.2020.05.001_bib131","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02510-16","article-title":"Inhibition by Avibactam and Clavulanate of the \u03b2-Lactamases KPC-2 and CTX-M-15 Harboring the Substitution N132G in the Conserved SDN Motif","volume":"61","author":"Ourghanlian","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.idc.2020.05.001_bib132","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1093\/jac\/dkx179","article-title":"Emergence of ceftazidime\/avibactam non-susceptibility in an MDR Klebsiella pneumoniae isolate","volume":"72","author":"Both","year":"2017","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"9","key":"10.1016\/j.idc.2020.05.001_bib133","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00357-18","article-title":"Combination of amino acid substitutions leading to CTX-M-15-mediated resistance to the ceftazidime-avibactam combination","volume":"62","author":"Compain","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.idc.2020.05.001_bib134","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1128\/AAC.02286-15","article-title":"Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC \u03b2-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014","volume":"60","author":"Karlowsky","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.idc.2020.05.001_bib135","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01814-18","article-title":"In\u00a0Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Latin American Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015","volume":"63","author":"Karlowsky","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.idc.2020.05.001_bib136","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1093\/jac\/dkz243","article-title":"Combination of MexAB-OprM overexpression and mutations in efflux regulators, PBPs and chaperone proteins is responsible for ceftazidime\/avibactam resistance in Pseudomonas aeruginosa clinical isolates from US hospitals","volume":"74","author":"Castanheira","year":"2019","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.idc.2020.05.001_bib137","doi-asserted-by":"crossref","first-page":"114835","DOI":"10.1016\/j.diagmicrobio.2019.05.007","article-title":"Longitudinal analysis of the in\u00a0vitro activity of ceftazidime-avibactam vs. Pseudomonas aeruginosa, 2012-2016","volume":"96","author":"Stone","year":"2020","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2020.05.001_bib138","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2020.25.2.1900766","article-title":"Detection in two hospitals of transferable ceftazidime-avibactam resistance in Klebsiella pneumoniae due to a novel VEB \u03b2-lactamase variant with a Lys234Arg substitution, Greece, 2019","volume":"25","author":"Voulgari","year":"2020","journal-title":"Euro Surveill"},{"issue":"12","key":"10.1016\/j.idc.2020.05.001_bib139","first-page":"3336","article-title":"Selection of mutants with resistance or diminished susceptibility to ceftazidime\/avibactam from ESBL- and AmpC-producing Enterobacteriaceae","volume":"73","author":"Livermore","year":"2018","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"11","key":"10.1016\/j.idc.2020.05.001_bib140","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1093\/jac\/dku237","article-title":"Activity of avibactam against Enterobacter cloacae producing an extended-spectrum class C \u03b2-lactamase enzyme","volume":"69","author":"Lahiri","year":"2014","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.idc.2020.05.001_bib141","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1093\/jac\/dkv004","article-title":"Selection and molecular characterization of ceftazidime\/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC","volume":"70","author":"Lahiri","year":"2015","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.idc.2020.05.001_bib142","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01822-19","article-title":"Dynamic emergence of mismatch repair deficiency facilitates rapid evolution of ceftazidime-avibactam resistance in Pseudomonas aeruginosa Acute infection","volume":"10","author":"Khil","year":"2019","journal-title":"mBio"},{"issue":"9","key":"10.1016\/j.idc.2020.05.001_bib143","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1128\/AAC.00548-15","article-title":"Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum \u03b2-lactamases, and porin mutations on the in\u00a0vitro activity of ceftazidime-avibactam against carbapenem-resistant K.\u00a0pneumoniae","volume":"59","author":"Shields","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.idc.2020.05.001_bib144","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.eimc.2016.09.013","article-title":"Activity of ceftazidime-avibactam against multidrug-resistance Enterobacteriaceae expressing combined mechanisms of resistance","volume":"35","author":"L\u00f3pez-Hern\u00e1ndez","year":"2017","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"6","key":"10.1016\/j.idc.2020.05.001_bib145","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00537-17","article-title":"Resistance to ceftazidime-avibactam in Klebsiella pneumoniae due to porin mutations and the increased expression of KPC-3","volume":"61","author":"Humphries","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.idc.2020.05.001_bib146","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00989-17","article-title":"Resistance to ceftazidime-avibactam is due to transposition of KPC in a porin-deficient strain of Klebsiella pneumoniae with increased efflux activity","volume":"61","author":"Nelson","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2020.05.001_bib147","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkz547","article-title":"Results of the Italian infection-Carbapenem Resistance Evaluation Surveillance Trial (iCREST-IT): activity of ceftazidime\/avibactam against Enterobacterales isolated from urine","author":"Giani","year":"2020","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.idc.2020.05.001_bib148","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01816-19","article-title":"Ceftazidime-avibactam resistance associated with increased blaKPC-3 gene copy number mediated by pKpQIL plasmid derivatives in ST258 Klebsiella pneumoniae","author":"Coppi","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.idc.2020.05.001_bib149","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1089\/mdr.2018.0439","article-title":"Assessment of the In\u00a0Vitro activities of ceftolozane\/tazobactam and ceftazidime\/avibactam in a collection of beta-lactam-resistant enterobacteriaceae and Pseudomonas aeruginosa Clinical Isolates at Montpellier University Hospital, France","volume":"25","author":"Viala","year":"2019","journal-title":"Microb Drug Resist"},{"issue":"8","key":"10.1016\/j.idc.2020.05.001_bib150","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1128\/AAC.02841-15","article-title":"Assessment of the In\u00a0Vitro Activity of Ceftazidime-Avibactam against Multidrug-Resistant Klebsiella spp. Collected in the INFORM Global Surveillance Study, 2012 to 2014","volume":"60","author":"Hackel","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.idc.2020.05.001_bib151","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02083-16","article-title":"Antimicrobial activity of ceftazidime-avibactam against gram-negative bacteria isolated from patients hospitalized with pneumonia in U.S. Medical Centers, 2011 to 2015","volume":"61","author":"Sader","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.idc.2020.05.001_bib152","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01045-17","article-title":"Antimicrobial activity of ceftazidime-avibactam tested against multidrug-resistant enterobacteriaceae and Pseudomonas aeruginosa Isolates from U.S. Medical Centers, 2013 to 2016","volume":"61","author":"Sader","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.idc.2020.05.001_bib153","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00389-17","article-title":"Unusual Escherichia coli PBP 3 Insertion Sequence Identified from a Collection of Carbapenem-Resistant Enterobacteriaceae Tested In\u00a0Vitro with a Combination of Ceftazidime-, Ceftaroline-, or Aztreonam-Avibactam","volume":"61","author":"Zhang","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.idc.2020.05.001_bib154","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/jac\/dku568","article-title":"Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam\/avibactam: role of a novel insertion in PBP3","volume":"70","author":"Alm","year":"2015","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"8","key":"10.1016\/j.idc.2020.05.001_bib155","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1128\/AAC.00220-16","article-title":"In Vitro Susceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014)","volume":"60","author":"Nichols","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.idc.2020.05.001_bib156","doi-asserted-by":"crossref","first-page":"6407","DOI":"10.1128\/AAC.01282-16","article-title":"Activity of Ceftazidime-Avibactam against Clinical and Isogenic Laboratory <\/i>Pseudomonas aeruginosa<\/i> Isolates Expressing Combinations of Most Relevant \u03b2-Lactam Resistance Mechanisms","volume":"60","author":"Torrens","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.idc.2020.05.001_bib157","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1128\/AAC.04238-14","article-title":"Unexpected challenges in treating multidrug-resistant gram-negative bacteria: resistance to ceftazidime-avibactam in archived isolates of Pseudomonas aeruginosa","volume":"59","author":"Winkler","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.idc.2020.05.001_bib158","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.ijantimicag.2018.07.027","article-title":"Loss of activity of ceftazidime-avibactam due to MexAB-OprM efflux and overproduction of AmpC cephalosporinase in Pseudomonas aeruginosa isolated from patients suffering from cystic fibrosis","volume":"52","author":"Chalhoub","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.idc.2020.05.001_bib159","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.2147\/IDR.S173804","article-title":"Multidrug-resistant Pseudomonas aeruginosa from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime-avibactam","volume":"11","author":"Atkin","year":"2018","journal-title":"Infect Drug Resist"},{"issue":"10","key":"10.1016\/j.idc.2020.05.001_bib160","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01379-18","article-title":"Mutation-driven evolution of Pseudomonas aeruginosa in the presence of either ceftazidime or ceftazidime-avibactam","volume":"62","author":"Sanz-Garc\u00eda","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.idc.2020.05.001_bib161","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00592-18","article-title":"In\u00a0vitro activity of ceftazidime-avibactam and aztreonam-avibactam against OXA-48-Carrying Enterobacteriaceae Isolated as Part of the International Network for Optimal Resistance Monitoring (INFORM) Global Surveillance Program from 2012 to 2015","volume":"62","author":"Kazmierczak","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.idc.2020.05.001_bib162","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00024-19","article-title":"OXA-48-mediated ceftazidime-avibactam resistance is associated with evolutionary trade-offs","volume":"4","author":"Fr\u00f6hlich","year":"2019","journal-title":"mSphere"},{"issue":"4","key":"10.1016\/j.idc.2020.05.001_bib163","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02243-16","article-title":"Can ceftazidime-avibactam and aztreonam overcome \u03b2-lactam resistance conferred by metallo-\u03b2-lactamases in enterobacteriaceae?","volume":"61","author":"Marshall","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.idc.2020.05.001_bib164","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01008-17","article-title":"Ceftazidime-avibactam and aztreonam, an interesting strategy to overcome \u03b2-lactam resistance conferred by metallo-\u03b2-lactamases in enterobacteriaceae and Pseudomonas aeruginosa","volume":"61","author":"Davido","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2020.05.001_bib165","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01426-19","article-title":"Searching for the optimal treatment for metallo- and serine-\u03b2-lactamase producing enterobacteriaceae: aztreonam in combination with ceftazidime-avibactam or meropenem-vaborbactam","author":"Biagi","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.idc.2020.05.001_bib166","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02369-16","article-title":"Low Frequency of Ceftazidime-Avibactam Resistance among Enterobacteriaceae Isolates Carrying blaKPC Collected in U.S. Hospitals from 2012 to 2015","volume":"61","author":"Castanheira","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2020.05.001_bib167","unstructured":"Melinta Therapeutics, Inc. VABOMERE (Meropenem and Vaborbactam) for Injection, for Intravenous Use. Lincolnshire (IL): 2019."},{"issue":"8","key":"10.1016\/j.idc.2020.05.001_bib168","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jama.2018.0438","article-title":"Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial","volume":"319","author":"Kaye","year":"2018","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.idc.2020.05.001_bib169","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1128\/AAC.33.2.215","article-title":"In\u00a0vitro antibacterial activity of SM-7338, a carbapenem antibiotic with stability to dehydropeptidase I","volume":"33","author":"Edwards","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.idc.2020.05.001_bib170","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1128\/AAC.00296-11","article-title":"Carbapenems: past, present, and future","volume":"55","author":"Papp-Wallace","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.idc.2020.05.001_bib171","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1021\/acs.jmedchem.5b00127","article-title":"Discovery of a Cyclic Boronic Acid \u03b2-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases","volume":"58","author":"Hecker","year":"2015","journal-title":"J\u00a0Med Chem"},{"issue":"11","key":"10.1016\/j.idc.2020.05.001_bib172","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01443-17","article-title":"Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae","volume":"61","author":"Lomovskaya","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.idc.2020.05.001_bib173","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01694-17","article-title":"Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae","volume":"61","author":"Sun","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.idc.2020.05.001_bib174","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ijantimicag.2018.02.021","article-title":"In\u00a0vitro activity of meropenem\/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem\/vaborbactam surveillance programme","volume":"52","author":"Pfaller","year":"2018","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"10.1016\/j.idc.2020.05.001_bib175","doi-asserted-by":"crossref","first-page":"4856","DOI":"10.1128\/AAC.00843-15","article-title":"Activity of Meropenem Combined with RPX7009, a Novel \u03b2-Lactamase Inhibitor, against Gram-Negative Clinical Isolates in New York City","volume":"59","author":"Lapuebla","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.idc.2020.05.001_bib176","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1093\/jac\/dky251","article-title":"In\u00a0vitro activity of meropenem combined with vaborbactam against KPC-producing Enterobacteriaceae in China","volume":"73","author":"Zhou","year":"2018","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"9","key":"10.1016\/j.idc.2020.05.001_bib177","doi-asserted-by":"crossref","first-page":"5454","DOI":"10.1128\/AAC.00711-16","article-title":"Effect of the \u03b2-Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae","volume":"60","author":"Castanheira","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.idc.2020.05.001_bib178","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01659-18","article-title":"Pharmacokinetics\/Pharmacodynamics of Vaborbactam, a Novel Beta-Lactamase Inhibitor, in Combination with Meropenem","volume":"63","author":"Griffith","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2020.05.001_bib179","article-title":"Early experience with meropenem-vaborbactam for treatment of carbapenem-resistant Enterobacteriaceae infections","author":"Shields","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2020.05.001_bib180","unstructured":"Merck & Co., Inc. RECARBRIO (imipenem, cilastatin, and relebactam) for injection, for intravenous Use. Whitehouse Station (NJ); 2019."},{"issue":"10","key":"10.1016\/j.idc.2020.05.001_bib181","first-page":"2286","article-title":"Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa","volume":"68","author":"Livermore","year":"2013","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.idc.2020.05.001_bib182","article-title":"RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem\/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections","author":"Motsch","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2020.05.001_bib183","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.bmcl.2013.12.101","article-title":"Discovery of MK-7655, a \u03b2-lactamase inhibitor for combination with Primaxin\u00ae","volume":"24","author":"Blizzard","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"issue":"8","key":"10.1016\/j.idc.2020.05.001_bib184","doi-asserted-by":"crossref","first-page":"5029","DOI":"10.1128\/AAC.00830-15","article-title":"Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City","volume":"59","author":"Lapuebla","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.idc.2020.05.001_bib185","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00642-17","article-title":"Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae","volume":"61","author":"Haidar","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.idc.2020.05.001_bib186","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1089\/mdr.2018.0065","article-title":"Effect of porins and blakpc expression on activity of imipenem with Relebactam in Klebsiella pneumoniae: can antibiotic combinations overcome resistance?","volume":"24","author":"Balabanian","year":"2018","journal-title":"Microb Drug Resist"},{"issue":"8","key":"10.1016\/j.idc.2020.05.001_bib187","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00573-18","article-title":"Clonal Background, Resistance Gene Profile, and Porin Gene Mutations Modulate In\u00a0Vitro Susceptibility to Imipenem-Relebactam in Diverse Enterobacteriaceae","volume":"62","author":"Gomez-Simmonds","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.idc.2020.05.001_bib188","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s10096-019-03517-y","article-title":"In\u00a0vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015-2016","volume":"38","author":"Galani","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2020.05.001_bib189","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02209-16","article-title":"In\u00a0Vitro Activity of imipenem-relebactam against gram-negative ESKAPE pathogens isolated by clinical laboratories in the united states in 2015 (results from the SMART global surveillance program)","volume":"61","author":"Lob","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.idc.2020.05.001_bib190","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1093\/jac\/dkz354","article-title":"Activity of imipenem\/relebactam against carbapenemase-producing Enterobacteriaceae with high colistin resistance","volume":"74","author":"Carpenter","year":"2019","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"7","key":"10.1016\/j.idc.2020.05.001_bib191","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1128\/AAC.05927-11","article-title":"In\u00a0vitro activity of MK-7655, a novel \u03b2-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria","volume":"56","author":"Hirsch","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.idc.2020.05.001_bib192","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/jac\/dkz133","article-title":"BSAC Resistance Surveillance Standing Committee. Potentiation of imipenem by relebactam for Pseudomonas aeruginosa from bacteraemia and respiratory infections","volume":"74","author":"Horner","year":"2019","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"9","key":"10.1016\/j.idc.2020.05.001_bib193","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1128\/AAC.36.9.2046","article-title":"Interplay of impermeability and chromosomal \u03b2-lactamase activity in imipenem-resistant Pseudomonas aeruginosa","volume":"36","author":"Livermore","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.idc.2020.05.001_bib194","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02406-17","article-title":"Inactivation of the Pseudomonas-Derived Cephalosporinase-3 (PDC-3) by Relebactam","volume":"62","author":"Barnes","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.idc.2020.05.001_bib195","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12866-019-1522-7","article-title":"In\u00a0vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa","volume":"19","author":"Young","year":"2019","journal-title":"BMC Microbiol"},{"issue":"2","key":"10.1016\/j.idc.2020.05.001_bib196","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.diagmicrobio.2017.02.018","article-title":"In\u00a0vitro activity of imipenem-relebactam against gram-negative bacilli isolated from patients with lower respiratory tract infections in the United States in 2015 - Results from the SMART global surveillance program","volume":"88","author":"Lob","year":"2017","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"7","key":"10.1016\/j.idc.2020.05.001_bib197","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/jac\/dky107","article-title":"In\u00a0vitro activity of imipenem\/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme","volume":"73","author":"Karlowsky","year":"2018","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.idc.2020.05.001_bib198","article-title":"In\u00a0vitro activity of imipenem-relebactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples - SMART Surveillance United States 2015-2017","author":"Karlowsky","year":"2019","journal-title":"J\u00a0Glob Antimicrob Resist"}],"container-title":["Infectious Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552020300301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552020300301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:17:28Z","timestamp":1760195848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891552020300301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":198,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0891552020300301"],"URL":"https:\/\/doi.org\/10.1016\/j.idc.2020.05.001","relation":{},"ISSN":["0891-5520"],"issn-type":[{"value":"0891-5520","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Resistance to Novel \u03b2-Lactam\u2013\u03b2-Lactamase Inhibitor Combinations","name":"articletitle","label":"Article Title"},{"value":"Infectious Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idc.2020.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}